In-Vivo CAR-T Cell Therapy: The Next Chapter in Oncology
Cell Therapy: Cancer’s New Arsenal Though several therapeutic, biotech, and medtech developments are changing the oncology landscape, in-vivo CAR-T cell therapy stands out for its precision, accessibility, and upscaling capabilities. A step up from ex vivo CAR-T cell therapy, it takes precedence due to its improved toxicity management, manufacturing parameters, and broader scope of clinical […]
In-vivo CAR-T Cell Therapy: New Frontier in Cancer Treatment
Chimeric antigen receptor T-cell (CAR-T) therapy transformed oncology by paving the path for harnessing patients’ own cells to treat B-cell lymphomas, leukemias, and other hematological malignancies. Traditionally, CAR-T cell therapy for cancer relied on ex vivo processes, where a patient’s T-cells are extracted, genetically reprogrammed in an external medium to express synthetic receptors targeting cancer […]
Therapeutic Potential of Epigenetic Reprogramming
Overview Epigenetic reprogramming is emerging as a promising approach to therapeutic innovation by modifying gene activity without altering the underlying DNA sequence. Advances in epigenome editing are enabling researchers to investigate how cellular functions can be redirected to address complex diseases. From cancer treatment to cardiovascular research and regenerative applications, multiple technologies are expanding the […]